Johnson & Johnson (JNJ) Long-Term Investments (2009)

Johnson & Johnson (JNJ) posted Long-Term Investments of $19.0 million for Q3 2009, up 5.56% sequentially from $18.0 million in Q2 2009.

Johnson & Johnson (JNJ) Long-Term Investments (2009) Analysis & Trends

Johnson & Johnson (JNJ) has 1 years of Long-Term Investments data on file, last reported at $19.0 million in Q3 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 3.12 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 268.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -12.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 1.11 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 983.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 1.63 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -24.00 Mn
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 465.60 Mn

Historic Data

Download Data
DateValue
Sep 27, 2009 19.00 Mn
Jun 28, 2009 18.00 Mn